GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » YoY EPS Growth

Shanghai Junshi Biosciences Co (HKSE:01877) YoY EPS Growth : 49.68% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Shanghai Junshi Biosciences Co's YoY EPS Growth for the quarter that ended in Mar. 2024 was 49.68%.

Shanghai Junshi Biosciences Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was HK$-0.32.

Shanghai Junshi Biosciences Co YoY EPS Growth Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co YoY EPS Growth Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EPS Growth
Get a 7-Day Free Trial 21.82 -126.58 59.08 -196.22 12.57

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 36.90 57.08 46.25 100.00 49.68

Shanghai Junshi Biosciences Co YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Shanghai Junshi Biosciences Co's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EPS Growth (A: Dec. 2023 )
=(Earnings per Share (Diluted) (A: Dec. 2023 )-Earnings per Share (Diluted) (A: Dec. 2022 ))/ | Earnings per Share (Diluted) (A: Dec. 2022 ) |
=(-2.538--2.903)/ | -2.903 |
=12.57 %

Shanghai Junshi Biosciences Co's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EPS Growth (Q: Mar. 2024 )
=(Earnings per Share (Diluted) (Q: Mar. 2024 )-Earnings per Share (Diluted) (Q: Mar. 2023 )) / | Earnings per Share (Diluted) (Q: Mar. 2023 )) |
=(-0.315--0.626)/ | -0.626 |
=49.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Junshi Biosciences Co YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » YoY EPS Growth
Comparable Companies
HKSE:01548 HKSE:09926 HKSE:09995 HKSE:01177 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 HKSE:09969 HKSE:01801 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8SJ:Germany 688180:China
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Website
https://www.junshipharma.com
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Executives
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd 2101 Beneficial owner
Jovial Champion Investments Limited 2201 Interest of corporation controlled by you
Gong Ruilin 2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited 2201 Interest of corporation controlled by you
Lvc Holdings Limited 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lvc Innovate Limited 2201 Interest of corporation controlled by you
Lin Lijun 2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp 2101 Beneficial owner
Lvc Renaissance Limited 2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited 2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines